Hormone replacement therapy after menopause: where the controversy stands now

The Short Version

The fear of hormone replacement therapy (HRT) that took hold in 2002 came mostly from one study, the Women's Health Initiative (WHI). Two OB-GYNs in these sources, Dr. Mary Claire Haver and Dr. Sara Gottfried, argue it was misdesigned, misreported and then misapplied to women it never tested [1][3]. Their reading of the later data is that timing decides almost everything. Women who start estrogen within about ten years of menopause, roughly ages 50 to 59, appear to get lower cardiovascular disease, better bones, less progression to diabetes and possibly brain benefits. Starting well after 60, once arteries have already built up plaque, carries more risk [1][3]. The cautions haven't gone away. Andrew Huberman stresses care around hormone-sensitive cancers and the need for blood work, and neuroscientist Lisa Mosconi says HRT may help some women but not all [2][4]. The real position now isn't HRT is safe for everyone but that every woman deserves an informed, individual conversation instead of an automatic "no" [1].

Table of contents

What They Said

Dr. Mary Claire Haver: "the worst misinformation campaign in the history of medicine"

Haver, a board-certified OB-GYN and menopause specialist, puts hormone therapy at the center of how she approaches menopause, and she's openly angry about how it was handled. She calls the fallout from the WHI "the worst misinformation campaign in the history of medicine" [1].

What the study set out to do, and who it enrolled. Observational data had suggested that women taking HRT had less cardiovascular disease, so the WHI set out to test that in a randomized trial [1]. Haver points to two design choices that made the results hard to apply to typical menopausal women:

• To keep the trial blinded, it excluded women with hot flashes, the very women who seek treatment.
• It enrolled women with an average age of 63, roughly 10 to 13 years past menopause [1].

What it actually found. In the estrogen-plus-progestin arm, breast cancer risk rose by a relative 25%, from about four to five cases per 1,000 women per year. Haver says that result was not statistically significant. In the estrogen-only arm, breast cancer fell by about 30% [1]. Both arms also had lower colon cancer rates, which got little attention [1].

How it was announced. Researchers announced the results at a press conference at the Watergate Hotel before the paper was published. "Estrogen causes breast cancer" became the top medical news story of 2002 [1].

How the picture changed. Haver says a 2020 American Heart Association analysis looked at the younger women in the data. In her words: "if you started hormone therapy between the ages of 50 to 59, you had a 50% decreased risk of cardiovascular disease and death from cardiovascular disease and all cause mortality" [1]. She calls this the timing hypothesis and sums it up: "estrogen is better at prevention than cure. And it's very protective, especially in the end of the coronary arteries" [1]. Her explanation of the flip side is careful. Once disease has built up, "there's some worry that adding estrogen once you've developed aftersclerosis or plaque might loosen the plaque, especially in that first year," which could mean a slightly higher stroke risk for some women. She adds right away: "It doesn't mean that after 60, you might not have cardiovascular benefit" [1].

She adds several points to the case for estrogen [1]:

• A British Medical Journal study linked longer lifetime estrogen exposure to better cognition.
• Estrogen itself isn't carcinogenic, as the huge estrogen levels of pregnancy show.
• Even after a breast cancer diagnosis, women are most likely to die of cardiovascular disease.

The damage to practice. Haver describes a generation of doctors who "weren't taught much about menopause, don't understand the protective benefits of estrogen and menopause's effect on metabolic disease. They have this mentality of estrogen is bad" [1]. She cites 2023 data on what happens when a woman reports classic menopausal symptoms to her doctor: "only 10% are offered any therapy" [1]. She also says the decades of fear let a market grow around the gap. There is "a lot of misunderstanding around what is bioidentical versus synthetic," and she describes "a lot of cottage industries in this little bubble that we had for 23 years where doctors were afraid to prescribe hormone therapy. And then women were desperate for care" [1]. She's wary of non-medical terms like "estrogen dominance" that grew up in that period [1]. Her guiding line: "Not every woman will choose HRT, but every woman deserves an informed conversation about it" [1].

Why the stakes reach past hot flashes. Haver describes perimenopause, which starts seven to 10 years before the last period, as a hormonal "zone of chaos." The ovaries resist the brain's signals, so estradiol spikes higher than ever and then crashes [1]. Serotonin, norepinephrine, dopamine and GABA systems all respond to estrogen and progesterone. She cites at least a 40% rise in mental health disorders and a doubling of SSRI use across the transition, and UK data that "one in five women will quit their jobs because of menopause symptoms" [1]. She notes emerging data that women given hormone therapy in perimenopause have less new-onset depression. Some neuroscientists now argue estrogen may work better than an SSRI for perimenopausal depression. For mood in perimenopause, her view is that estrogen for stabilization, rather than antidepressants, appears to be the best treatment [1].

The most extreme case is premature ovarian insufficiency, when ovarian function fails before age 40. "The longer your body is away from estrogen, the higher the risk factor," she says. Untreated, it's linked to earlier death from cardiovascular disease, diabetes and stroke, "All because estrogen is so protective and they have to go so long without it. We can back negate most of those risks by giving her aggressive hormone therapy early" [1]. For these women she uses doses three to four times higher than typical menopause doses, aiming for estradiol around 100 picograms per milliliter or higher [1].

How she actually prescribes. Haver's practical approach is where the "new" HRT differs most from the 2002 version [1]:

• Route matters. Oral estrogen passes through the liver and can slightly raise clotting factors. She generally prefers patches, gels, sprays, or a vaginal ring that treats both locally and systemically. She avoids oral estrogen entirely in women with a clotting history or genes like factor V Leiden.
• Protect the uterus. Women with a uterus must also take a progestogen. She prefers progesterone itself, taken orally at night, because it appears to calm the brain through GABA and improve sleep.
• Dose by symptoms, not a lab target. There are no established estradiol targets for menopause (premature ovarian insufficiency is the exception), so she adjusts doses to symptoms.
• Watch other hormones. For a patient on thyroid medication, she rechecks thyroid levels in six weeks "because giving you back estrogen is going to mess with a little bit of that feedback cycle" [1].
• Testosterone for women. There is no FDA-approved form for women in the U.S., so she prescribes a compounded transdermal cream (about $30 a month in Texas), aiming for roughly 50 to 70 nanograms per deciliter. She watches for acne, chin hair or voice changes. It helps low sexual desire, and she uses it off label for bone and muscle loss. For hypoactive sexual desire disorder, "most of my patients choose testosterone" over the two FDA-approved drugs, largely because of cost [1].
• Perimenopause is less settled. Here "it's a little bit of the Wild West," she says: whether to use a contraceptive dose that suppresses ovulation or a lower menopause dose. The goal of the lower dose is giving "just enough estrogen to calm the brain down and tell them everything's okay" and avoiding the big peaks and drops [1].

Local vaginal estrogen. On this Haver is least hedged. She says it's extremely safe, isn't absorbed in clinically significant amounts, and should be used by essentially every woman [1]. It treats the genitourinary syndrome of menopause, is the best treatment for recurrent urinary tract infections in menopause, helps urge incontinence, and could, she believes, keep many women out of the ER with urosepsis. Prasterone (Intrarosa), a vaginal DHEA, is an option often chosen for breast cancer survivors [1].

Who shouldn't take it, and when to stop. Her contraindications are [1]:

• hormone-sensitive cancers
• unexplained abnormal uterine bleeding, which must be evaluated first
• active blood clots
• severe liver disease

A history of breast cancer is a nuanced conversation, not an automatic disqualification. Women over 60 or more than 10 years past menopause can still consider HRT after screening, such as a coronary calcium score or carotid ultrasound, because estrogen will "always protect her bones," urinary system and skin [1]. As for stopping: "I will probably die with my estradiol patch on," she says, unless a contraindication develops [1]. She adds that HRT also appears to reduce vertigo, dry eye and frozen shoulder. Women on HRT alongside a GLP-1 drug lose 30% more weight [1].

Dr. Sara Gottfried: "the wrong study in the wrong patients with the wrong medications"

Gottfried, a Harvard-trained OB-GYN and integrative medicine professor, reaches the same overall verdict as Haver. She makes the case through the study's design and the specific drugs it used.

The collapse in use. After the WHI was published in 2002, "we went from a huge number of women taking hormone therapy to a very small percentage like in the range of 5%. And that means we've got millions, millions of women who are suffering needlessly with things like insomnia, difficulty with their mood, difficulty with sex drive" [3].

Her critique of the trial. She calls it "the wrong study in the wrong patients with the wrong medications and with some of the wrong outcomes" [3]. She makes several technical points:

• It "was powered to look at cardiovascular outcomes, it was not powered to look at breast cancer," yet it was stopped because of breast cancer risk [3].
• "What happened in the control arm of the study was that they had an incredibly low rate of breast cancer," which made the treatment arm look worse by comparison at five years [3].
• It used synthetic hormones: conjugated equine estrogen (Premarin) and medroxyprogesterone acetate. She believes the synthetic progestin in particular is associated with the greater breast cancer risk [3].
• Later re-evaluations, 18 years out, point to the control-group problem and no increased breast cancer risk. Women who took estrogen alone (those who'd had a hysterectomy) "actually had a decreased breast cancer risk and decreased breast cancer mortality" [3].

Timing. Gottfried's version of the timing effect closely matches Haver's. Women aged 50 to 60, within 10 years of menopause, "seem to have the greatest benefit" [3]:

• less subclinical atherosclerosis, so less cardiovascular disease
• better bone health
• less progression to diabetes

Over 60, "they started to have greater risk of certain outcomes, such as cardiovascular disease, myocardial infarction, and so on" [3]. Her bottom line is that hormone therapy in "forms that are similar to which your body always made when it's given judiciously at the right time, typically within 5 to 10 years of menopause, which is 51 to 52. That is incredibly safe" [3].

Hot flashes as a warning sign. Gottfried goes further than Haver in one direction: she wants to change who gets offered treatment. She objects to the conventional approach, which grew out of the WHI, of withholding hormone therapy unless hot flashes or night sweats are severe: "I just want to call that out. I would say no, that is not the way to approach it" [3]. She rejects the idea that these symptoms are passing nuisances to be handled with "suck it up, suck it up" and advice to "turn down the temperature in the room" [3]. Instead, she says, hot flashes and night sweats are markers of cardiovascular disease, and "They are a biomarker of increased bone loss. They are a biomarker of changes in the brain" [3]. Many perimenopausal symptoms, she adds, are not driven by the ovaries: "They are driven by the brain" [3].

The brain and Alzheimer's. Citing Lisa Mosconi's work at Cornell, Gottfried describes about a 20% average decline in brain glucose metabolism from before to after menopause, greatest in women with the worst hot flashes and night sweats. She calls this "slow brain energy." With a mother and grandmother who had Alzheimer's, she follows this closely [3]. Her concern: "women are scared to death of taking hormone therapy. And we've got all of these women that are marching toward potentially a greater risk of Alzheimer's disease. And they have this opportunity in their 40s and their 50s to take hormone therapy and they may not be offered it" [3]. She and Huberman raise an open question: could this brain hypometabolism be addressed with estrogen, better metabolic flexibility, or both? They leave it as a question, not a finding [3].

Know your baseline. Gottfried wants women in their 30s to get a hormonal baseline so they know what to aim for later. "I don't usually go exactly back to where the estrogen and progesterone levels were, but we can get pretty close," she says [3]. She also recommends a coronary artery calcium score by 45 for women and men [3]. That's relevant because Haver uses the same test to screen older women considering HRT [1].

Andrew Huberman: benefits vary, respect the cancer risk, test

In his solo episode on sex hormones, Huberman takes a more guarded, mechanism-first stance [2]. Menopause brings a large drop in circulating estrogen as the ovaries' output declines. The result is hot flashes, mood swings, migraine headaches and brain fog that "can be very very disruptive" [2]. The most common response, he notes, is that "physicians will prescribe supplemental estrogen so this is hormone therapy where somebody takes either oral estrogen or they'll take it or use a patch or a pellet" [2].

His emphasis is that results vary. Some people respond very well, while others run into challenges and side effects [2]. He urges caution for anyone with a family history of breast cancer, since many breast cancers are estrogen dependent. That's why drugs that block aromatase or estrogen receptors were developed [2]. His broader reasoning is about tissue biology. Tissues that constantly renew cells, such as the breast, uterine lining and ovaries, "are particularly vulnerable to the development of cancers." When thinking about optimizing estrogen and testosterone, "more is definitely not better" [2]. He also warns that these hormones run on negative feedback, so "getting blood work done is extremely important. It for safety reasons and also just to know whether or not things are working" [2].

In the Gottfried conversation, Huberman sums up his understanding of the large trials: "if the hormone therapy was started early enough, it was very beneficial for vitality and health outcomes," whereas starting after menopause "could be detrimental." Gottfried confirmed this, with the refinements above [3].

Dr. Lisa Mosconi: the brain's stake, and not every woman responds

Mosconi, a neuroscientist who studies women's brains, frames menopause as a neurological transition, not just a reproductive one [4]. Nearly two-thirds of Alzheimer's patients are women. She says this isn't just because women live longer. Estrogen drives energy metabolism, immune response, neuroplasticity and glucose processing in the brain, and women lose it steeply, whereas men's hormones decline gradually [4]. "Estrogen isn’t just a reproductive hormone. It’s a superpower for your brain" [4].

Her view of HRT is measured. For some women, cognitive function recovers after menopause. For others it deteriorates into early signs of Alzheimer's. HRT may help some women but not all, and phytoestrogens from food, found in flaxseeds, sesame seeds, chickpeas, soy, dried figs and apricots, may be a gentler alternative [4]. She also flags that women who go through surgical menopause show a higher risk of dementia, especially without supportive therapy [4]. That matches Haver's point that losing estrogen early and abruptly is the riskiest situation [1].

Where They Agree, and Where They Don't

Where they agree.

• The WHI didn't show what the headlines said. Haver and Gottfried both say the trial's population, drugs and communication distorted its message. Both say the estrogen-only arm actually showed lower breast cancer risk [1][3].
• Timing is the key variable. Both say starting within about ten years of menopause, roughly 50 to 60, is where the benefits cluster, and both put the extra risk in women starting later [1][3]. Huberman's own summary of the trials agrees [3].
• Too few women are treated. Gottfried puts HRT use at about 5% after 2002, and Haver says only 10% of symptomatic women are offered any therapy today [1][3].
• Estrogen matters for the brain. Haver, Gottfried and Mosconi all tie estrogen loss to mood, cognition or Alzheimer's risk [1][3][4].
• Early or surgical loss of estrogen is especially harmful. Haver on premature ovarian insufficiency and Mosconi on surgical menopause both make this point [1][4].

Where they differ.

• The breast cancer finding in the combined arm. Haver says the combined arm's 25% relative increase wasn't statistically significant [1]. Gottfried accepts there was an apparent increased risk at five years but blames the unusually low rate in the control group and the synthetic progestin. She says later reanalysis shows no increased risk [3]. Huberman doesn't enter the WHI debate at all. He treats breast cancer risk, especially with a family history, as a standing reason for caution [2]. The differences come partly from vantage point: the two OB-GYNs are reinterpreting a specific trial, while Huberman is making a general biological point about hormone-sensitive tissue.
• Women over 60. Gottfried's summary of the data is simply that over 60, risks rise [3]. Haver is more open. Older women can still consider HRT after screening such as a calcium score, and "It doesn't mean that after 60, you might not have cardiovascular benefit" [1]. Both agree the vascular concern is real. They differ on how firm a line 60 should be.
• Breast cancer history. Huberman urges caution with even a family history of breast cancer [2]. Haver lists hormone-sensitive cancers as a contraindication, but treats a personal history of breast cancer as a nuanced conversation, not an automatic no. She offers vaginal DHEA as an option for survivors [1].
• How universal the benefit is. Haver and Gottfried speak of estrogen as broadly protective when started on time [1][3]. Mosconi says HRT helps some women but not all and points to food-based phytoestrogens as a gentler route [4]. Huberman likewise says some people respond very well and others have challenges and side effects [2].
• Who should be offered it. Gottfried rejects the rule of treating only severe hot flashes and wants the conversation to include heart, bone and brain risk [3]. Haver's phrase is that every woman deserves an informed conversation, not that every woman should take it [1].
• "Estrogen dominance." Gottfried uses the concept, mostly for younger women, as a driver of fibroids, endometriosis and breast pain [3]. Haver warns about "estrogen dominance" as a non-medical term that grew up during the decades when doctors avoided HRT [1].

Why It Works

The sources give several mechanisms for why estrogen replacement can help and why timing matters:

• Vascular protection is preventive, not curative. Estrogen protects blood vessels, especially the coronary arteries, before plaque builds up. After atherosclerosis has developed, adding estrogen may destabilize plaque in the first year, which is why a late start carries a small stroke concern [1]. Gottfried's reading of the data, less subclinical atherosclerosis in women who start at 50 to 60 and more heart attacks and cardiovascular disease after 60, fits the same pattern [3].
• The brain runs on estrogen. Neurotransmitter systems for serotonin, norepinephrine, dopamine and GABA respond to estrogen and progesterone. The erratic swings of perimenopause explain the anxiety, depression, brain fog and executive-function problems many women report [1]. Mosconi adds that estrogen supports brain energy metabolism, glucose processing, immune response and neuroplasticity [4]. Gottfried cites a roughly 20% drop in brain glucose metabolism across menopause, greatest in the women with the worst hot flashes [3]. Steadying estrogen gives the brain back a stable signal. As Haver puts it, the aim is to "calm the brain down" [1].
• Hot flashes come from the brain. Vasomotor symptoms reflect disruption of the hypothalamus's temperature-control center. Hormone therapy, which returns estrogen, is the gold-standard treatment [1]. Gottfried reads the same symptoms as markers of cardiovascular, bone and brain change, not just discomfort [3].
• Route changes risk. Oral estrogen passes through the liver and can slightly raise clotting factors. Transdermal forms avoid that first pass, which is why Haver prefers them and avoids oral estrogen in women prone to clotting [1].
• The progestogen matters. Women with a uterus need a progestogen to protect the lining [1]. Gottfried believes the synthetic medroxyprogesterone acetate used in the WHI, more than estrogen itself, is associated with breast cancer risk [3]. Haver prefers progesterone itself, which appears to calm the brain through GABA and help sleep [1].
• Some tissues are hormone-sensitive. Tissues with high cell turnover, like breast and uterine lining, are more prone to cancers that are often hormone sensitive. This is the biological basis for the caution Huberman urges [2].
• Hormones run on feedback. Changing one hormone shifts others: estrogen alters thyroid needs [1], and too much of a sex hormone can suppress the signals that drive the body's own production [2]. That's why monitoring matters.

Where It Applies, and Where It Doesn't

Where the case is strongest:

• Women within about ten years of menopause, roughly ages 50 to 59, with no contraindications. This is where both OB-GYNs place the heart, bone, metabolic and mortality benefits [1][3].
• Women with bothersome vasomotor symptoms, for whom hormone therapy is the gold standard [1].
• Women with premature ovarian insufficiency or early surgical menopause. Here going without estrogen carries its own risks, including cardiovascular disease, diabetes, stroke and dementia, and therapy is usually needed at higher doses [1][4].
• Genitourinary symptoms and recurrent urinary tract infections, where local vaginal estrogen is, in Haver's view, appropriate for almost everyone [1].
• Perimenopausal mood problems, where emerging data suggest estrogen may reduce new-onset depression, though Haver calls dosing in perimenopause "a little bit of the Wild West" [1].

Where more care, or a different path, is needed:

• Women with hormone-sensitive cancers, unexplained abnormal bleeding, active clots or severe liver disease [1].
• Women with a clotting history or factor V Leiden, who should avoid oral estrogen specifically [1].
• Women starting more than ten years after menopause or after 60. The data show more risk here, though Haver says screening with a calcium score or carotid ultrasound can still open the door [1][3].
• Women with a personal or family history of breast cancer. Here Huberman urges caution [2] and Haver calls for a careful, individual conversation [1].
• Women who simply don't respond well. Mosconi and Huberman both note HRT doesn't help everyone [2][4]. Mosconi offers phytoestrogen-rich foods as a gentler option [4].

These sources describe general evidence and their own clinical practice. Anyone considering hormone therapy should work it out with a qualified clinician who knows her personal and family history.

What To Do With It

1. Ask for the conversation, not just a prescription. Bring up hormone therapy with your doctor directly. Haver's data suggest only 10% of symptomatic women are offered therapy unless they ask [1]. If your doctor dismisses it by pointing to the 2002 study, ask how the WHI's age range (average 63) and synthetic hormones apply to you [1][3].
2. Pay attention to timing. If you're in your late 40s or early 50s, or your periods are changing, have the discussion now. The benefits both OB-GYNs describe cluster in women who start within about ten years of menopause [1][3].
3. Don't write off symptoms as nuisances. Track hot flashes, night sweats, sleep, mood, brain fog and joint pain. Gottfried treats them as signals of heart, bone and brain change [3], and Haver says perimenopause is diagnosed by symptoms, since blood tests are unreliable during the "zone of chaos" [1].
4. Ask about route and type. Discuss transdermal estrogen (patch, gel or spray) versus oral, especially if you have any clotting history. If you have a uterus, ask about progesterone itself, which Haver takes at night for sleep [1].
5. Screen first if you're older. If you're over 60 or more than ten years past menopause, ask about a coronary artery calcium score or carotid ultrasound before deciding [1]. Gottfried recommends a calcium score for everyone by 45 anyway [3].
6. Ask about vaginal estrogen separately. For dryness, painful sex, urge incontinence or recurrent UTIs, Haver considers local vaginal estrogen extremely safe and appropriate for nearly every woman [1].
7. Get baseline labs and keep monitoring. Gottfried recommends a hormone baseline in your 30s so you know what to aim for [3]. Huberman stresses blood work before and during any hormone change [2]. If you take thyroid medication, have levels rechecked about six weeks after starting estrogen [1].
8. Weigh your cancer history honestly. With a personal history of hormone-sensitive cancer, or a strong family history of breast cancer, go through the specific risks and alternatives, such as vaginal DHEA, with a specialist [1][2].
9. If early menopause hits, act quickly. If periods stop before 40, or after a hysterectomy or removal of the ovaries, ask to be evaluated for premature ovarian insufficiency. Haver describes a patient who went 18 months without a diagnosis [1], and the risks grow the longer the body goes without estrogen [1][4].
10. Support the brain in other ways too. Whether or not you choose HRT, Mosconi's food-based approach adds its own protection: phytoestrogens, berries, leafy greens, omega-3s, hydration and fewer processed foods [4].

Sources

1. Dr Mary Claire Haver How To Navigate Menopause Perimenopause For Maximum Health Vitality · Huberman Lab
2. How to Optimize Testosterone & Estrogen | Huberman Lab Essentials · Huberman Lab
3. Dr Sara Gottfried How To Optimize Female Hormone Health For Vitality Longevity · Huberman Lab
4. Optimize Your Brain Health & How to Prevent Alzheimer's with Dr. Lisa Mosconi · The School of Greatness